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Abstract
Background: Patient-reported outcomes (PROs) are captured within cancer trials to help future patients and their clinicians
make more informed treatment decisions. However, variability in standards of PRO trial design and reporting threaten the
validity of these endpoints for application in clinical practice.
Methods: We systematically investigated a cohort of randomized controlled cancer trials that included a primary or
secondary PRO. For each trial, an evaluation of protocol and reporting quality was undertaken using standard checklists.
General patterns of reporting where also explored.
Results: Protocols (101 sourced, 44.3%) included a mean (SD) of 10 (4) of 33 (range ¼ 2–19) PRO protocol checklist items.
Recommended items frequently omitted included the rationale and objectives underpinning PRO collection and approaches
to minimize/address missing PRO data. Of 160 trials with published results, 61 (38.1%, 95% confidence interval ¼ 30.6% to
45.7%) failed to include their PRO findings in any publication (mean 6.43-year follow-up); these trials included 49 568 partici-
pants. Although two-thirds of included trials published PRO findings, reporting standards were often inadequate according to
international guidelines (mean [SD] inclusion of 3 [3] of 14 [range ¼ 0–11]) CONSORT PRO Extension checklist items). More
than one-half of trials publishing PRO results in a secondary publication (12 of 22, 54.5%) took 4 or more years to do so follow-
ing trial closure, with eight (36.4%) taking 5–8 years and one trial publishing after 14 years.
Conclusions: PRO protocol content is frequently inadequate, and nonreporting of PRO findings is widespread, meaning
patient-important information may not be available to benefit patients, clinicians, and regulators. Even where PRO data are
published, there is often considerable delay and reporting quality is suboptimal. This study presents key recommendations
to enhance the likelihood of successful delivery of PROs in the future.
Patient-reported outcomes (PROs) are increasingly captured
within cancer trials to provide the patient perspective on
the physical, functional, psychological, and social conse-
quences of disease and treatment (1). This information is
important in supporting patients to make more informed
treatment decisions at the point of cancer diagnosis and
beyond (2,3).
The utility of such data has been recognized by patients,
clinicians, funders, regulators, and policy makers (4–8). Despite
this, emerging evidence suggests that important PRO informa-
tion may be omitted from protocols (9,10), potentially impairing
data collection (11,12), and that PRO results are poorly reported
in trial publications (5,13–21) or may not be reported at all (22).
This represents a waste of limited health-care and research
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resources and may restrict the effective uptake of PRO trial find-
ings in practice.
The American Society of Clinical Oncology, United Kingdom
National Institute for Health and Care Excellence, and European
Medicines Agency have all outlined the need to improve the
quality of PRO trial results to better inform technology apprais-
als and licensing decisions (8,23,24). Most importantly, patients
with cancer have called for greater availability of high-quality
PRO trial data to help them gain insight into what their life will
actually be like during and after a certain therapy as well as
how long they may survive (25).
It has been hypothesized that omission of key PRO protocol
components may be an important contributor to suboptimal
PRO reporting (26). To our knowledge, however, only one study
has examined this relationship in a small (n¼ 26) sample of
ovarian cancer trials (10). Furthermore, a recent study has
assessed the issue of availability of PRO trial data across
Germany, Switzerland, and Canada but did not evaluate PRO
protocol quality, so the relationship between the two could not
be determined (22). To investigate these issues, we conducted a
systematic evaluation of PRO protocol content and reporting
across a cohort of completed international cancer trials.
Methods
Search Strategy and Extraction
We identified randomized controlled cancer trials in the
National Institute for Health Research (NIHR) Portfolio that in-
cluded a PRO primary or secondary outcome [study protocol
available (26)]. The NIHR is the largest UK public funding
stream, comparable to the National Institutes of Health in the
United States. Trials were eligible if they were listed as closed
on the database by March 2014 (scheduled to allow time for
reporting to occur) and/or had published results by the time of
our final publication search in June 2017. We excluded trials
lacking random allocation to one of two or more groups, or a
control arm, and those that terminated early.
For each trial, we attempted to source the trial protocol (final
ethically approved version), published articles reporting final
results, and secondary publications reporting PRO results. We
defined a primary publication as the first or principal publica-
tion of the trial results regarding the primary outcome(s) and
secondary publications as those published following/in support
of the primary article. Abstracts and reports of preliminary
results were excluded. Protocol retrieval was attempted via di-
rect contact with research teams and by searching trial regis-
tries, databases, and websites (see Supplementary Box 1,
available online). Publications were obtained via direct author
contact or by searching MEDLINE, Embase, Cinahlþ, PsycINFO,
Cochrane Controlled Trials Register, or the Patient-Reported
Outcome Measures Over Time In Oncology Registry (27). Full
search details are provided in the Supplementary Methods
(available online).
All searching, sourcing, and extraction were conducted by
two independent investigators (TK and KA), with a third re-
searcher (DK, MC, or AR) involved where required. Investigators
extracted trial characteristics and determined the availability of
PRO trial results. Unreported PROs were defined as those that
were prespecified in the NIHR Portfolio database, trial registry,
or trial protocol but that were not reported in either a primary
or secondary publication. The University of Birmingham (Ref:
ERN_17–0085A) gave ethical approval for this study.
Data Analysis
Investigators evaluated the completeness of general protocol
sections using the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) 2013 checklist (28).
Completeness of PRO-specific content was evaluated using a
PRO protocol checklist (9). For publications, general reporting
standards were evaluated using the 2010 Consolidated
Standards of Reporting Trials (CONSORT) checklist (29). PRO-
specific aspects were reviewed using the 2013 CONSORT-PRO
Extension (30). For each trial protocol or publication assessed,
individual checklist items were described as “present” or
“absent,” and one point was assigned for each item “present”
giving a total score. Protocol and reporting standards did not
make a distinction between study phases; however, investiga-
tors noted where a checklist item was deemed “not applicable”
according to the study design (eg, SPIRIT item 17a on blinding
for a nonblinded study), and the denominator was adjusted ac-
cordingly during the analysis. Inter-rater agreement was calcu-
lated for each checklist based on the proportion of matching
item-level decisions. A full breakdown of checklists is provided
in Supplementary Figures 1 and 2 (available online). It should be
noted that many included trials would have been developed be-
fore the existence of the SPIRIT/PRO protocol and CONSORT PRO
standards used in this study. Although developed recently, they
present consolidated criteria drawn from many preceding years
of published research outlining commonly considered good
practice; thus, they remain a useful metric by which to assess
the quality of PRO trial design and reporting.
Statistical Analysis
Descriptive data are reported as numbers and percentages and
where appropriate are summarized using means (SDs) or 95%
confidence intervals (CIs). We performed three prespecified ex-
ploratory regression models including those trials for which a
matching protocol and publication had been retrieved.
Backwards elimination with a P-to-eliminate value of greater
than .05 was used to select variables to be included in all mod-
els. All tests were 2-sided. All analyses were conducted in
STATA version 12 (StataCorp, College Station, TX).
Model A investigated protocol inclusion of PRO protocol
checklist items. The independent variable was the PRO Protocol
Checklist score (adjusted for denominator variation), and the in-
dependent variables were year of the protocol, whether the PRO
was named as a primary or secondary outcome, cancer spe-
cialty, trial sample size, funding source, and the SPIRIT checklist
score (adjusted for denominator variation).
Model B used logistic regression to determine factors associ-
ated with the reporting of PRO trial results. The dependent vari-
able was “PRO trial results reported in the principal trial
publication (yes/no).” Covariates included year of the protocol,
whether the PRO was named as a primary or secondary out-
come, cancer specialty, trial sample size, funding source, the
SPIRIT checklist score (adjusted for denominator variation),
whether the primary outcome of the trial was statistically sig-
nificant, and the PRO protocol checklist score (adjusted for de-
nominator variation).
Model C explored factors associated with publication adher-
ence to the CONSORT-PRO Extension. The dependent variable
was the CONSORT-PRO Extension score (adjusted for denomina-
tor variation). Covariates included the year of publication,
whether the PRO was named as a primary or secondary
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outcome, whether there were single or multiple reports, trial
sample size, funding source, journal impact factor, the
CONSORT 2010 checklist score (adjusted for denominator varia-
tion), and the PRO protocol checklist score (adjusted for denomi-
nator variation). Full model details are provided in the
Supplementary Methods (available online).
Results
Data Screening and Sourcing
The NIHR Portfolio included 1141 trials up to March 1, 2014,
of which 913 were excluded because they were not random-
ized controlled trials, did not include a PRO, or had not been
completed by the cutoff date (Figure 1). The final sample in-
cluded 228 trials, recruiting across 72 countries, which used
262 different measures to collect PRO data (see Table 1 for
trial characteristics and Supplementary Tables 1–3 (available
online) for full sample details and checklist scoring results).
We were able to source 101 of 228 protocols (44.3%): 73 from
the named trial contact, 13 as a supplementary journal file, 1
from the trial website, 5 from the sponsor/funder, and 9 using a
Google search. Eighty percent of sourced protocols were associ-
ated with trials closing in 2008 or later, which was comparable
to the overall sample. In addition, the demographics of trials
where we were able to source the protocol vs those where the
protocol was unavailable were broadly similar (Table 2). There
were, however, some exceptions. Compared with the overall
sample, studies for which we retrieved the protocol were less
likely to be industry funded and included slightly fewer breast
and prostate cancer trials, but slightly more lung, colorectal,
and ovarian cancer trials. Finally, interrater agreement for all
checklists was high (75%).
PRO Protocol Content
Trial protocols (n¼ 101) included a mean (SD) of 32 (6) of 51
(range¼ 11–43) SPIRIT 2013 recommendations (66.2% adjusted
for denominator variation) and 10 (4) of 33 (range¼ 2–19) PRO
protocol checklist items (31.9% adjusted). There were a number
of PRO items deemed important in the literature (31) that were
frequently omitted, for example, the rationale for PRO collection
(missing in 68.2% of protocols), description of PRO-specific
objectives (missing in 83.1%), justification of the choice of PRO
instrument with regard to the study hypothesis (missing in
66.2%) and questionnaire measurement properties (missing in
48.5%), information regarding PRO data collection plans (miss-
ing in 40.7%), and methods to reduce avoidable missing PRO
data (missing in 61.1%) (Figure 2). Where a PRO was the primary
outcome, protocols included an adjusted mean of 62.4% SPIRIT
recommendations and 38.3% PRO protocol checklist items.
Where a PRO was the secondary outcome, protocols included
an adjusted mean of 67.0% SPIRIT recommendations and 30.4%
PRO protocol checklist items.
Reporting of PRO Trial Results
With a mean of 6.43 years of follow-up from trial closure, 160
trials had published their primary results by the time of our fi-
nal publication search (Figure 1). Eighty-five trials included their
PRO findings in the primary publication. Eight trials published
their PRO data in both a primary and secondary publication and
14 solely in a secondary publication. More than one-third, 61 of
160 (38.1%, 95% CI ¼ 30.6% to 45.7%), failed to include their PRO
findings in any publication; these trials included 49 568
participants. More than one-half of trials publishing their PRO
results in a secondary publication (12 of 22, 54.5%) took 4 or
more years to do so following trial closure, with eight (36.4%)
taking 5–8 years and one trial publishing after 14 years.
Figure 1. Study flow diagram. CONSORT ¼ Consolidated Standards of Reporting Trials; NIHR ¼ National Institute for Health Research; PRO ¼ patient-reported outcome;
RCT ¼ randomized controlled trial; SPIRIT ¼ Standard Protocol Items: Recommendations for Interventional Trials.
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Where a PRO was a primary outcome, 27 of 32 (84.4%) trials
included PRO findings in the primary publication. Two trials
(6.3%) published their PRO data in both a primary and secondary
publication, two (6.3%) solely in a secondary publication, and
three (9.4%) failed to include their PRO findings in any publica-
tion. Mean time from trial closure to publication of PRO results
in a primary publication was 3 years vs 8 years for a secondary
publication.
Where a PRO was a secondary outcome, 58 of 128 (45.3%) trials
included PRO findings in the primary publication. Six trials (4.7%)
published their PRO data in both a primary and secondary publi-
cation, 12 (9.4%) solely in a secondary publication, and 58 (45.3%)
failed to include their PRO findings in any publication. Mean time
from trial closure to publication of PRO results in a primary publi-
cation was 4 years vs 5 years for a secondary publication.
Publications included a mean (SD) of 23 (4) of 37 (range ¼ 13–
32) CONSORT 2010 items (63.0% adjusted for denominator varia-
tion) and 3 (3) of 14 (range ¼ 0–11) CONSORT-PRO Extension
checklist items (21.7% adjusted). Commonly omitted CONSORT-
PRO Extension items included description of the PRO hypothe-
sis/objectives (missing in 71.8% of publications), evidence of the
validity and reliability of the PRO instrument(s) (missing in
67.8%), detail regarding the number of PRO data collected at
baseline and subsequent time points (missing in 72.8%), and de-
scription of the statistical approaches used to deal with missing
PRO data (missing in 67.8%) (Figure 3). Where a PRO was the pri-
mary outcome, publications included an adjusted mean of
62.1% of CONSORT 2010 items and 41.1% CONSORT-PRO items.
Where a PRO was the secondary outcome, protocols included
an adjusted mean of 63.3% of CONSORT 2010 items and 16.9%
CONSORT-PRO checklist items.
Factors Associated with PRO Protocol Content and
Reporting
Eighty-four trials were included in the prespecified exploratory
regression analyses. Full details of each model are presented in
Supplementary Tables 4–6 (available online).
Table 1. Characteristics of included trials (n¼ 228)
Characteristic Trials, No. (%)
Trial phase
II 32 (14.0)
II/III 17 (7.5)
III 151 (66.2)
Other 28 (12.3)
Recruitment regions*
United Kingdom 221 (96.9)
Spain 65 (28.5)
Italy 63 (27.6)
Canada 62 (27.2)
France 62 (27.2)
Germany 58 (25.4)
United States 55 (24.1)
Belgium 54 (23.7)
Australia 51 (22.4)
Poland 47 (20.6)
Russian Federation 43 (18.9)
Netherlands 41 (18.0)
Korea, Republic of 34 (14.9)
Brazil 30 (13.2)
Austria 29 (12.7)
Sweden 29 (12.7)
Argentina 28 (12.3)
Israel 28 (12.3)
Czech Republic 26 (11.4)
Hungary 25 (11.0)
China 24 (10.5)
Japan 24 (10.5)
Taiwan 24 (10.5)
Turkey 24 (10.5)
Cancer type
Breast 37 (16.2)
Lung 28 (12.3)
Prostate 21 (9.2)
Colorectal 15 (6.6)
Ovarian 14 (6.1)
Other 115 (50.4)
Source of funding†
Industry only 79 (34.6)
Public only 34 (14.9)
Charity only 85 (37.3)
Mixed 30 (13.2)
PRO
Primary outcome 42 (18.4)
Secondary outcome only 186 (81.6)
Both 28 (12.3)
PROs measured
Quality of life 163 (71.5)
Symptom burden 128 (56.1)
Anxiety and depression 24 (10.5)
Other 12 (5.3)
PRO questionnaires used
EORTC QLQ-C30 95 (41.7)
EQ-5D 54 (23.7)
HADS 21 (9.2)
Other 92 (40.4)
Year of trial closure
2001 2 (0.9)
2002 5 (2.2)
2003 4 (1.8)
2004 3 (1.3)
2005 12 (5.3)
(continued)
Table 1. (continued)
Characteristic Trials, No. (%)
2006 9 (3.9)
2007 8 (3.5)
2008 20 (8.8)
2009 23 (10.1)
2010 32 (14.0)
2011 34 (14.9)
2012 34 (14.9)
2013 38 (16.7)
2014 4 (1.8)
*Additional recruitment regions included in less than 10% of trials: Greece,
Switzerland, New Zealand, Ireland, Mexico, Singapore, Hong Kong, India,
Thailand, Denmark, Romania, Portugal, South Africa, Finland, Chile, Norway,
Peru, Slovak Republic, Ukraine, Bulgaria, Colombia, Croatia, Estonia, Puerto Rico,
Philippines, Latvia, Egypt, Guatemala, Luxembourg, Panama, Serbia, Slovenia,
Bosnia and Herzegovina, Costa Rica, Cyprus, Lebanon, Lithuania, Malaysia, Saudi
Arabia, Bahamas, Belarus, Ecuador, Indonesia, Macedonia, Pakistan, Tunisia, and
Uruguay. See Supplementary Appendix (available online) for additional informa-
tion. EORTC QLQ = European Organization for the Research and Treatment of
Cancer Quality of Life Questionnaire; EQ-5D = EuroQol Five Dimension prefer-
ence-based health status measure; HADS = Hospital Anxiety and Depression
Scale; NIHR ¼ National Institute for Health Research; PRO ¼ patient-reported
outcome.
†As listed on the NIHR Portfolio Database.
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For model A, statistically significant predictors of the proto-
col inclusion of PRO protocol checklist items included presence
of the PRO as a primary outcome (coef. ¼ 10.93, 95% CI ¼ 4.46 to
17.41), later year of the protocol (coef. ¼ 0.82, 95% CI ¼ 1.52 to
0.12), a higher adjusted SPIRIT 2013 checklist score (coef. ¼
0.41, 95% CI ¼ 0.20 to 0.62), and larger sample size (reference cat-
egory <100; n¼ 100–499, coef. ¼ 9.77, 95% CI ¼ 1.84 to 17.71;
n¼ 500–999, coef. ¼ 14.14, 95% CI ¼ 5.04 to 23.24; n> 1000, coef.
¼ 6.50, 95% CI ¼ 2.70 to 15.70). Statistically nonsignificant
covariates included cancer specialty and funding source.
For model B, increased odds of publishing PRO results were
associated with inclusion of the PRO as a primary outcome
(odds ratio [OR] ¼ 5.68, 95% CI ¼ 1.09 to 29.5). With charity fund-
ing as a reference category, industry funding (OR ¼ 0.24, 95% CI
¼ 0.07 to 0.87) and mixed-funding (OR ¼ 0.17, 95% CI ¼ 0.04 to
0.66) were associated with decreased odds of publishing PRO
results. Statistically nonsignificant covariates included year of
the protocol, cancer specialty, trial sample size, adjusted SPIRIT
checklist score, whether the primary outcome of the trial was
statistically significant, and the adjusted PRO protocol checklist
score.
For model C, a higher adjusted PRO protocol checklist score
was a statistically significant predictor of reporting quality, as
measured by the CONSORT PRO Extension (coef. ¼ 0.44, 95% CI
¼ 0.01 to 0.87). Statistically nonsignificant covariates included
year of publication, whether the PRO was named as a primary
or secondary outcome, whether there were single or multiple
reports, trial sample size, funding source, journal impact factor,
and the adjusted CONSORT 2010 checklist score.
Discussion
In this study evaluating PRO protocol quality and reporting in can-
cer clinical trials, several key messages emerged. Nonreporting of
PRO trial results was widespread, PRO protocol components were
often inadequate, and where published PRO data were available,
there was often considerable delay and standards of reporting
were poor.
More than one-third of trials failed to include their PRO find-
ings in either a primary or secondary publication. Thus, valu-
able information that may have an important impact on
Table 2. Trial demographics stratified by availability of protocol
Characteristic
Protocol sourced
No. (%)
No protocol available
No. (%)
Total 101 (100.0) 127 (100.0)
Trial phase
II 14 (13.9) 18 (14.2)
II/III 8 (7.9) 9 (7.1)
III 66 (65.3) 85 (66.9)
Other 13 (12.9) 15 (11.8)
Cancer type
Breast 12 (11.9) 25 (19.7)
Lung 16 (15.8) 12 (9.4)
Prostate 8 (7.9) 13 (10.2)
Colorectal 11 (10.9) 4 (3.1)
Ovarian 8 (7.9) 6 (4.7)
Other 46 (45.5) 67 (52.8)
Source of funding*
Industry only 19 (18.8) 60 (47.2)
Public only 18 (17.8) 16 (12.6)
Charity only 45 (44.6) 40 (31.5)
Mixed 19 (18.8) 11 (8.7)
PRO
Primary outcome 19 (18.8) 23 (18.1)
Secondary outcome only 82 (81.2) 104 (81.9)
Both 15 (14.9) 13 (10.2)
Year of trial closure
2001 1 (1.0) 1 (0.8)
2002 1 (1.0) 4 (3.1)
2003 2 (2.0) 2 (1.6)
2004 1 (1.0) 2 (1.6)
2005 6 (5.9) 6 (4.7)
2006 5 (5.0) 4 (3.1)
2007 5 (5.0) 3 (2.4)
2008 10 (9.9) 10 (7.9)
2009 12 (11.9) 11 (8.7)
2010 13 (12.9) 19 (15.0)
2011 15 (14.9) 19 (15.0)
2012 15 (14.9) 19 (15.0)
2013 14 (13.9) 24 (18.9)
2014 1 (1.0) 3 (2.4)
*As listed on the National Institute for Health Research Portfolio Database. PRO
¼ patient-reported outcome.
Figure 2. Percentage of protocols (n¼101) including each patient-reported outcome (PRO) protocol checklist item (adjusted for denominator variation). PROM ¼ pa-
tient-reported outcome measure; CRF = case report form.
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treatment decision-making and outcomes may not be available
to patients and their clinicians or to researchers undertaking
meta-analyses. This represents a waste of limited health-care
research resources. Moreover, it devalues the considerable con-
tribution of trial participants who spend time and effort provid-
ing PRO information in the belief that the data will be used for
the benefit of future patients. Worryingly, we found almost
50 000 patients were involved in studies that failed to publish
their PRO data. Nonreporting of these important patient data is
unethical.
Our results concur with findings from a previous smaller
study that reviewed 90 cancer trials collecting quality-of-life
PROs conducted in Switzerland, Germany, and Canada be-
tween 2000 and 2003 and a recent study evaluating PRO
reporting across 11 major journals (22,32). Our methodology
has the added value of being able to evaluate the quality of
included PRO protocols and publications and the association
between the PRO protocol quality and reporting as well as to
track the time from trial closure to publication of PRO
results.
Our results identify a failure to include comprehensive PRO
information in many trial protocols and publications. These
findings concur with previous studies evaluating the quality of
PRO protocols and publications in both cancer and noncancer
settings (9–11,13–21,33). Rudimentary design elements were
consistently omitted from protocols reviewed in this study, in-
cluding a clear PRO rationale or objectives, justification for the
choice of measure, guidance on data collection, and, crucially,
aspects around prevention or analysis of missing PRO data,
which has been identified as a particular problem in trials col-
lecting PROs (34). These omissions may impair PRO-specific trial
conduct, reduce data quality (11,35,36), and threaten the validity
of these endpoints for application in clinical practice. Our
exploratory regression analysis suggested an association be-
tween PRO-specific protocol completeness and reporting, which
supports our a priori hypothesis (26). We postulate that the in-
clusion of “good-quality” PRO protocol components facilitates
more robust data collection, lower rates of avoidable missing
data, and more informative data with which to generate mean-
ingful, publishable, PRO reports. The publication of the SPIRIT-
PRO Extension in 2018 provides consensus recommendations
regarding items that should be included in trial protocols in
which PROs are a primary or key secondary outcome (37). In ad-
dition, open access international reporting guidelines are avail-
able via the 2013 CONSORT PRO Extension (30). It is hoped the
existence of these standards will help improve the complete-
ness and homogeneity of PRO design and reporting in the
future.
Alongside the current study, we conducted 44 follow-up qual-
itative interviews (Retzer A, Calvert M, Ahmed K, Keeley T,
Armes J, Brown JM, Calman L, Gavin G, Glaser AW, Greenfield
DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F,
Mercieca-Bebber R, King MT, Turner G, Kyte D. unpublished data)
with journal editors, funder representatives, international PRO
methodology experts, people with lived experience of cancer,
and trialists based in Austria, Canada, Belgium, the Netherlands,
Spain, the United States, and the United Kingdom. The protocol
is available (38), and results will be published elsewhere. The
qualitative data suggest the reasons underpinning our concern-
ing findings are multi-factorial, aligning with related research in
this area (11,12,35,39). In summary, interviewees suggested that
future trials collecting PROs should include more comprehensive
PRO trial design and protocol development involving PRO exper-
tise and patient input, with a focus on standardized administra-
tion, minimizing burden, preventing/addressing missing data,
development of a priori PRO analyses and dissemination plans,
Figure 3. Percentage of publications (n¼99) including each Consolidated Standards of Reporting Trials (CONSORT) patient-reported outcomes (PRO) Extension
Checklist item (adjusted for denominator variation). *PRO elaboration to CONSORT checklist item 2a: “Scientific background and explanation of rationale.” †PRO elabo-
ration to CONSORT checklist item 4a: “Eligibility criteria for participants.” ‡PRO elaboration to CONSORT checklist item 7a: “How sample size was determined.” §PRO
elaboration to CONSORT checklist item 13a: “For each group, the numbers of participants who were randomly assigned, received intended treatment, and were ana-
lyzed for the primary outcome.” kPRO elaboration to CONSORT checklist item 15: “A table showing baseline demographic and clinical characteristics for each group.”
¶PRO elaboration to CONSORT checklist item 16: “For each group, number of participants (denominator) included in each analysis and whether the analysis was by
original assigned groups.” #PRO elaboration to CONSORT checklist item 17a: “For each primary and secondary outcome, results for each group, the estimated effect
size, and its precision (such as 95% confidence interval).” **PRO elaboration to CONSORT checklist item 18: “Results of any other analyses performed, including sub-
group analyses and adjusted analyses, distinguishing pre-specified from exploratory.”
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and training of all staff involved. We concur with these sugges-
tions and propose several further methodological recommenda-
tions below (summarized in Figure 4).
Our study had limitations. We were unable to source all pro-
tocols in our sample either due to an out-of-date database or
registry information or because researchers refused to provide
the document. The PRO protocol checklist we used was a pre-
cursor to the internationally endorsed SPIRIT-PRO Extension,
published after our study had taken place. However, SPIRIT-PRO
represents minimum standards, whereas the PRO protocol
checklist is more comprehensive and was developed by experts
in the field following a large-scale systematic review (31). Most
included studies were developed before the publication of the
PRO protocol and CONSORT-PRO checklists. However, as no
other internationally endorsed PRO-specific consensus guide-
lines or checklists existed at the time of our study, we believe
their use is justified. Moreover, they provide a useful bench-
mark that may help leverage improvements in future trials col-
lecting PROs. Although the criteria for publication and reporting
of phase II and III trials can be different, the reporting standards
we employed did not make a distinction between these study
designs. To mitigate, investigators agreed where a checklist
item was deemed “not applicable” according to the study design
and the denominator was adjusted accordingly during the anal-
ysis. NIHR Portfolio trials are predominantly United Kingdom-
led; thus, replication of our study results in other countries is
needed to demonstrate generalizability. The confidence inter-
vals for predictors in our exploratory regression models were
quite wide; this should be considered when interpreting the
results and reflect the spectrum of quality observed with regard
to protocol content and reporting. It should be noted that the
most recent trials included in our sample closed 3 years before
our final literature search in June 2017. It may be that some
studies went on to publish their PRO data after this cutoff,
which should be considered when interpreting our results. We
would, however, argue that even reporting delays of this magni-
tude may impair the uptake of PRO trial results in practice and
contravene recent regulatory and funder requirements mandat-
ing publication of results within 12 months of trial completion
(40,41).
Our findings suggest that nonreporting of PRO trial findings
is widespread, and concerns surrounding standards of PRO pro-
tocol content and reporting in cancer clinical trials appear valid.
Thus, valuable patient-centered information may not be avail-
able to aid the decision-making of patients, clinicians, and regu-
lators. These deficiencies must be urgently addressed to ensure
these data are made available to enhance clinical outcomes for
the benefit of future patients.
We therefore recommend that researchers utilize the re-
cently published SPIRIT-PRO Extension (37) alongside the
Figure 4. Summary of key recommendations and resources. CONSORT ¼ Consolidated Standards of Reporting Trials; CPROR ¼ Centre for Patient-Reported Outcomes
Research; FDA ¼ Food & Drug Administration; EMA ¼ European Medicines Agency; ISOQOL ¼ International Society for Quality of Life Research; PPI = patient and public
involvement; PRO ¼ patient-reported outcome; SISAQOL ¼ Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints
Data; SPIRIT ¼ Standard Protocol Items: Recommendations for Interventional Trials.
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original SPIRIT 2013 statement (28,42) when developing protocols
for trials including PROs. For reporting, we encourage the use of
the CONSORT-PRO (30) Extension alongside CONSORT (43).
Evidence suggests that the use of such checklists may be valu-
able in driving up standards of PRO research (44). We urge fun-
ders and journals to endorse and enforce the use of SPIRIT-PRO
and CONSORT-PRO and to promote and facilitate prompt publi-
cation of PRO findings, preferably as part of the main trial report.
Finally, we encourage all stakeholders to utilize the growing
range of suitable open access PRO training resources and guide-
lines to support high-quality PRO research and dissemination.
Funding
This work was supported by project funding from Macmillan
Cancer Support (grant number 5592105). The study funder did
not have any role in the study design; the collection, analysis,
and interpretation of data; the writing of the report; or the deci-
sion to submit the article for publication.
Notes
Affiliations of authors: Centre for Patient-Reported Outcomes
Research, Institute of Applied Health Research, University of
Birmingham, Birmingham, UK (DK, AR, KA, TK, GT, MC); UK
National Cancer Research Institute (NCRI) Psychosocial
Oncology and Survivorship CSG subgroup: Understanding and
Measuring the Consequences of Cancer and Its Treatment, UK
(DK, JA, LC, AG, AWG, DMG, AL, RMT); School of Health Sciences,
University of Surrey, Guildford, UK (JA); Clinical Trials Research
Unit, University of Leeds, Leeds, UK (JMB); Macmillan
Survivorship Research Group, Health Sciences, University of
Southampton, Highfield Campus, Southampton, UK (LC); N.
Ireland Cancer Registry, Centre for Public Health, Queens
University, Belfast, Northern Ireland (AG); Leeds Institute of
Cancer and Pathology, University of Leeds, Leeds, UK (AWG,
GV); Sheffield Teaching Hospital NHS Foundation Trust and
University of Sheffield, Sheffield, UK (DMG); UCL Elizabeth
Garrett Anderson Institute for Women’s Health, Medical School
Building, University College London, London, UK (AL); Cancer
Clinical Trials Unit, University College London Hospitals NHS
Foundation Trust, London, UK (RMT); Queen’s Department of
Oncology School of Medicine, Queen’s Cancer Research
Institute, Kingston, Ontario, Canada (MB); Italian Group for
Adult Hematologic Diseases (GIMEMA), Health Outcomes
Research Unit, Rome, Italy (FE); Sydney Medical School,
University of Sydney and Psycho-oncology Co-operative
Research Group, School of Psychology, Faculty of Science,
University of Sydney, Sydney, Australia (RMB, MTK); NHMRC
Clinical Trials Centre, University of Sydney, Sydney, Australia
(RMB); NIHR Birmingham Biomedical Research Centre,
University Hospitals Birmingham NHS Foundation Trust and
University of Birmingham, Birmingham, UK (DK, MC).
The funders had no role in design of the study; the collec-
tion, analysis, and interpretation of the data; the writing of the
manuscript; and the decision to submit the manuscript for pub-
lication. All authors had full access to all of the data in the study
and take responsibility for the integrity of the data and the ac-
curacy of the data analysis. The lead author affirms that this
manuscript is an honest, accurate, and transparent account of
the study being reported; that no important aspects of the study
have been omitted; and that any discrepancies from the study
as planned have been explained.
DK, AR, KA, TK, and MC were supported by project funding
from Macmillan Cancer Support. JA, LC, AGa, AGl, DK, AL, RT,
and DG are all members of the National Cancer Research
Institute Psychosocial Oncology and Survivorship CSG sub-
group: Understanding and measuring the consequences of can-
cer and its treatment. FE reports personal fees from Bristol-
Myers Squibb, grants and personal fees from TEVA, grants from
Amgen, personal fees from Orsenix, and personal fees from
Incyte outside the submitted work. GV and JB report grants from
the National Institute for Health Research (NIHR) and Yorkshire
Cancer Research and in addition GV receives personal fees from
Roche, Genentech, Eisai, and Novartis. MC reports grants from
Macmillan Cancer Support, Innovate UK, the NIHR, NIHR
Birmingham Biomedical Research Centre and NIHR Surgical
Reconstruction and Microbiology Research Centre (SRMRC) at
the University of Birmingham and University Hospitals
Birmingham NHS Foundation Trust, and personal fees from
Astellas, Takeda, and Merck outside the submitted work. DK
reports grants from Macmillan Cancer Support, Innovate UK,
the NIHR, NIHR Birmingham Biomedical Research Centre, and
NIHR SRMRC at the University of Birmingham and University
Hospitals Birmingham NHS Foundation Trust, and personal fees
from Merck outside the submitted work.
The study was initially conceived by members of the UK
National Cancer Research Institute (NCRI) Psychosocial
Oncology and Survivorship CSG subgroup: Understanding and
measuring the consequences of cancer and its treatment (JA,
LC [chair], AGa, AGl, DG, DK, AL, and RT). DK, MC, JA, LC, Aga,
AGl, DG, AL, and RT acquired funding. DK and MC designed
the study. KA, TK, AR, and GT undertook data extraction and
analysis with input from DK and MC. DK drafted the first man-
uscript, with all authors contributing to subsequent iterations.
All authors provided critical input on the manuscript and ap-
proved the final version for publication. DK or MC is
guarantor.
We thank the researchers who responded to our requests for
information and trial documentation. We also thank Anita
Walker for her administrative support and Dr Richard Lehman
for his comments on the manuscript.
References
1. Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on core patient-reported
outcomes in cancer clinical trials: symptomatic adverse events, physical func-
tion, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553–1558.
2. Basch, E., 2013. Toward patient-centered drug development in oncology. N
Engl J of Medi. 369(5): 397–400.
3. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs
clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;
101(23):1624–1632.
4. Ahmed S, Berzon RA, Revicki DA, et al. The use of patient-reported outcomes
(PRO) within comparative effectiveness research: implications for clinical
practice and health care policy. Med Care. 2012;50(12):1060–1070.
5. Brundage M, Leis A, Bezjak A, et al. Cancer patients’ preferences for commu-
nicating clinical trial quality of life information: a qualitative study. Qual Life
Res. 2003;12(4):395–404.
6. FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical
Product Development to Support Labeling Claims. 2009. http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM193282.pdf. Accessed March 2019.
7. Ouwens M, Hermens R, Hulscher M, et al. Development of indicators for
patient-centred cancer care. Support Care Cancer. 2010;18(1):121–130.
8. European Medicines Agency. Appendix 2 to the guideline on the evaluation of anti-
cancer medicinal products in man: the use of patient-reported outcome (PRO) meas-
ures in oncology studies. 2016. https://www.ema.europa.eu/en/documents/
other/appendix-2-guideline-evaluation-anticancer-medicinal-products-
man_en.pdf. Accessed March 2019.
9. Kyte D, Duffy H, Fletcher B, et al. Systematic evaluation of the patient-
reported outcome (PRO) content of clinical trial protocols. PLoS One. 2014;
9(10):e110229.
A
R
T
IC
LE
8 | JNCI J Natl Cancer Inst, 2019, Vol. 111, No. 11
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz038/5430934 by U
niversity C
ollege London user on 05 July 2019
10. Mercieca-Bebber R, Friedlander M, Kok PS, et al. The patient-reported out-
come content of international ovarian cancer randomised controlled trial
protocols. Qual Life Res. 2016;25(10):2457–2465.
11. Kyte D, Ives J, Draper H, et al. Inconsistencies in quality of life data collection
in clinical trials: a potential source of bias? Interviews with research nurses
and trialists. PLoS One. 2013;8(10):e76625.
12. Mercieca-Bebber R, Kyte D, Calvert M, et al. Administering patient-reported
outcome questionnaires in Australian cancer trials: the roles, experiences,
training received and needs of site coordinators. Trials. 2017;18(suppl 1):O30.
13. Bylicki O, Gan HK, Joly F, et al. Poor patient-reported outcomes reporting
according to CONSORT guidelines in randomized clinical trials evaluating
systemic cancer therapy. Ann Oncol. 2015;26(1):231–237.
14. Dirven L, Taphoorn MJ, Reijneveld JC, et al. The level of patient-reported out-
come reporting in randomised controlled trials of brain tumour patients: a
systematic review. Eur J Cancer. 2014;50(14):2432–2448.
15. Efficace F, Fayers P, Pusic A, et al. Quality of patient-reported outcome report-
ing across cancer randomized controlled trials according to the CONSORT
patient-reported outcome extension: a pooled analysis of 557 trials. Cancer.
2015;121(18):3335–3342.
16. Efficace F, Feuerstein M, Fayers P, et al. Patient-reported outcomes in rando-
mised controlled trials of prostate cancer: methodological quality and impact
on clinical decision making. Eur Urol. 2014;66(3):416–427.
17. Efficace F, Jacobs M, Pusic A, et al. EORTC Quality of Life Group. Patient-
reported outcomes in randomised controlled trials of gynaecological cancers:
investigating methodological quality and impact on clinical decision-mak-
ing. Eur J Cancer. 2014 Jul 1;50(11):1925–1941.
18. Joly F, Vardy J, Pintilie M, et al. Quality of life and/or symptom control in ran-
domized clinical trials for patients with advanced cancer. Ann Oncol. 2007;
18(12):1935–1942.
19. Mercieca-Bebber RL, Perreca A, King M, et al. Patient-reported outcomes in
head and neck and thyroid cancer randomised controlled trials: a systematic
review of completeness of reporting and impact on interpretation. Eur J
Cancer. 2016;56:144–161.
20. Smith AB, Cocks K, Parry D, et al. Reporting of health-related quality of life
(HRQOL) data in oncology trials: a comparison of the European Organization
for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and
the Functional Assessment of Cancer Therapy-General (FACT-G). Qual Life
Res. 2014;23(3):971–976.
21. Weing€artner V, Dargatz N, Weber C, et al. Patient reported outcomes in ran-
domized controlled cancer trials in advanced disease: a structured literature
review. Expert Rev Clin Pharmacol. 2016;9(6):821–829.
22. Schandelmaier S, Conen K, von Elm E, et al. Planning and reporting of
quality-of-life outcomes in cancer trials. Ann Oncol. 2015;26(9):
1966–1973.
23. ASCO. ASCO Value Framework Update. 2016. http://www.asco.org/advocacy-
policy/asco-in-action/asco-value-framework-update. Accessed August 2017.
24. Keetharuth A, Dixon S, Winter M, et al. Effects of cancer treatment on quality
of life (ECTQOL): final results. decision support unit, University of Sheffield
2014. http://www.nicedsu.org.uk/DSU_Cancer_utilities_ECTQoL_final_re-
port_SEPT_2014.pdf. Accessed August 2015.
25. Wilson R. Patient led PROMs must take centre stage in cancer research. Res
Involv Engagem. 2018;4(1):7.
26. Ahmed K, Kyte D, Keeley T, et al. Systematic evaluation of patient-reported
outcome (PRO) protocol content and reporting in UK cancer clinical trials: the
EPiC study protocol. BMJ Open. 2016;6(9):e012863.
27. Efficace F, Rees J, Fayers P, et al. Overcoming barriers to the implementation
of patient-reported outcomes in cancer clinical trials: the PROMOTION regis-
try. Health Qual Life Outcomes. 2014;12(1):86.
28. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining
standard protocol items for clinical trials. Ann Inter Med. 2013. Feb
5;158(3):200–207.
29. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomized trials. Jpn Pharmacol Ther.
2015;43(6):883–891.
30. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient reported out-
comes in randomised trials: the CONSORT PRO extension. JAMA. 2013;309(8):
814–822.
31. Calvert M, Kyte D, Duffy H, et al. Patient-reported outcome (PRO) assessment
in clinical trials: a systematic review of guidance for trial protocol writers.
PLoS One. 2014;9(10):e110216.
32. Marandino L, La Salvia A, Sonetto C, et al. Deficiencies in health-related qual-
ity-of-life assessment and reporting: a systematic review of oncology ran-
domized phase III trials published between 2012 and 2016. Ann Oncol. 2018;
29(12):2288–2295.
33. Brundage M, Bass B, Davidson J, et al. Patterns of reporting health-related
quality of life outcomes in randomized clinical trials: implications for clini-
cians and quality of life researchers. Qual Life Res. 2011;20(5):653–664.
34. Fairclough D, Peterson HF, Chang V. Why are missing quality of life data a
problem in clinical trials of cancer therapy? Stat Med. 1998;17(5–7):667–677.
35. Kyte D, Ives J, Draper H, et al. Current practices in patient-reported outcome
(PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff
and management. BMJ Open. 2016;6(10):e012281.
36. Kyte D, Ives J, Draper H, et al. Management of patient-reported outcome
(PRO) alerts in clinical trials: a cross sectional survey. PLoS One. 2016;11(1):
e0144658.
37. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of
patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO exten-
sion. JAMA. 2018;319(5):483–494.
38. Retzer A, Keeley T, Ahmed K, et al. Evaluation of patient-reported outcome
protocol content and reporting in UK cancer clinical trials: the EPiC study
qualitative protocol. BMJ Open. 2018;8(2):e017282.
39. Friedlander M, Mercieca-Bebber R, King M. Patient-reported outcomes (PRO)
in ovarian cancer clinical trials—lost opportunities and lessons learned. Ann
Oncol. 2016;27(suppl 1):i66–i71.
40. EU. Posting of Clinical Trial Summary Results in European Clinical Trials Database
(EudraCT) to Become Mandatory for Sponsors as of 21 July 2014 2014. https://www.
ema.europa.eu/en/news/posting-clinical-trial-summary-results-european-
clinical-trials-database-eudract-become-mandatory. Accessed December 2018.
41. MRC. Written Evidence Submitted by the Medical Research Council (RES0041):
Research Integrity and Clinical Trials Transparency. 2018. http://data.parliament.
uk/writtenevidence/committeeevidence.svc/evidencedocument/science-
and-technology-committee/research-integrity/written/77043.html.
Accessed December 2018.
42. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elabo-
ration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
43. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guide-
lines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):
e1000251.
44. Mercieca-Bebber R, Rouette J, Calvert M, et al. Preliminary evidence on the
uptake, use and benefits of the CONSORT-PRO extension. Qual Life Res. 2017;
26(6):1427–1437.
A
R
T
IC
LE
D. Kyte et al. | 9
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz038/5430934 by U
niversity C
ollege London user on 05 July 2019
